AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21946897 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS7 low risk (n=188)
Number of subjects: 938
Study 21946897 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS7 high risk
Number of subjects: 938
Study 21946897 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS7
Number of subjects: 938
Study 19216762 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions implemented in workplaces
Number of subjects: 0
Study 17682247 — intervention group
Group type: COMPARATOR
Intervention: Feedback tip sheet only
Number of subjects: 10144
Study 17682247 — intervention group
Group type: COMPARATOR
Intervention: Tip sheet plus Rate Your Plate (RYP)
Number of subjects: 10144
Study 17682247 — intervention group
Group type: COMPARATOR
Intervention: Tip sheet, RYP, plus Let's Eat Kit (LEK)
Number of subjects: 10144
Study 17682247 — intervention group
Group type: COMPARATOR
Intervention: All written materials plus CD audio intervention (AUD)
Number of subjects: 10144
Study 17682247 — intervention group
Group type: EXPERIMENTAL
Intervention: All written materials plus counseling from a trained lay person (LAY-C)
Number of subjects: 10144
Study 17682247 — intervention group
Group type: EXPERIMENTAL
Intervention: All written materials plus counseling by a nutritionist (NUT-C)
Number of subjects: 10144
Study 17682247 — intervention group
Group type: COMPARATOR
Intervention: Total sample
Number of subjects: 10144
Study 17682247 — intervention group
Group type: COMPARATOR
Intervention: Participants with borderline-high BC levels
Number of subjects: 10144
Study 17682247 — intervention group
Group type: COMPARATOR
Intervention: Participants with high BC levels
Number of subjects: 10144
Study 17682247 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic participants in the audio condition
Number of subjects: 10144
Study 12562958 — intervention group
Group type: COMPARATOR
Intervention: Postmenopausal no-HRT
Number of subjects: 103
Study 12562958 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal HRT
Number of subjects: 103
Study 11686653 — intervention group
Group type: EXPERIMENTAL
Intervention: Clock Drawing Test scoring systems (Freedman et al., 1994; Libon et al., 1996; Rouleau et al., 1992)
Number of subjects: 20
Study 9481276 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline (NS) instillation during endotracheal suctioning
Number of subjects: 25
Study 9481276 — intervention group
Group type: COMPARATOR
Intervention: No instillation of normal saline during endotracheal suctioning
Number of subjects: 25
Study 8323889 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge Whitacre needle
Number of subjects: 400
Study 8323889 — intervention group
Group type: COMPARATOR
Intervention: 25-gauge Quincke needle
Number of subjects: 400
Study 8323889 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 400
Study 3552360 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluradoline, 300 mg
Number of subjects: 0
Study 3552360 — intervention group
Group type: COMPARATOR
Intervention: Aspirin, 650 mg
Number of subjects: 0
Study 3552360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3552360 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluradoline, 150 mg
Number of subjects: 0
Study 29429534 — intervention group
Group type: EXPERIMENTAL
Intervention: Parboiled rice (PBR)
Number of subjects: 0
Study 29429534 — intervention group
Group type: COMPARATOR
Intervention: White rice (WR)
Number of subjects: 0
Study 29429534 — intervention group
Group type: COMPARATOR
Intervention: Brown rice (BR)
Number of subjects: 0
Study 26804788 — intervention group
Group type: EXPERIMENTAL
Intervention: High-SR writing task followed by high-SR voice task
Number of subjects: 104
Study 26804788 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-SR writing task followed by high-SR voice task
Number of subjects: 104
Study 26804788 — intervention group
Group type: EXPERIMENTAL
Intervention: High-SR writing task followed by relaxation intervention and high-SR voice task
Number of subjects: 104
Study 24929459 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint injection of phylloquinone (vitamin K1) in SP6
Number of subjects: 4
Study 22587416 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy plus concurrent chemoradiotherapy (69 patients)
Number of subjects: 144
Study 22587416 — intervention group
Group type: EXPERIMENTAL
Intervention: Aurora-A and HIF-1α co-overexpression
Number of subjects: 144
Study 20234166 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17380190 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute multidisciplinary group intervention (four 1.5-hour sessions)
Number of subjects: 127
Study 17380190 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard medical care)
Number of subjects: 127
Study 17380190 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute multidisciplinary group intervention
Number of subjects: 127
Study 15618067 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis
Number of subjects: 1462
Study 15618067 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI
Number of subjects: 1462
Study 12000208 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 40
Study 12000208 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 40
Study 9928561 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary endocrine therapy
Number of subjects: 0
Study 9928561 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant endocrine therapy
Number of subjects: 0
Study 9928561 — intervention group
Group type: EXPERIMENTAL
Intervention: Faslodex
Number of subjects: 0
Study 9928561 — intervention group
Group type: EXPERIMENTAL
Intervention: Arimidex
Number of subjects: 0
Study 7706955 — intervention group
Group type: EXPERIMENTAL
Intervention: Phasic exercises and chiropractic therapy (Group 2, n = 15)
Number of subjects: 30
Study 7706955 — intervention group
Group type: COMPARATOR
Intervention: Standard exercises (stretching/isometric/isokinetic) and chiropractic therapy (Group 1, n = 15)
Number of subjects: 30
Study 2533024 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunoxaprofen 400 mg/day p.o. for 30 days
Number of subjects: 20
Study 2533024 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg/day p.o. for 30 days
Number of subjects: 20
Study 1266667 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mug digoxin
Number of subjects: 39
Study 1266667 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg pentazocine
Number of subjects: 39
Study 1266667 — intervention group
Group type: COMPARATOR
Intervention: bumetanide
Number of subjects: 39
Study 1266667 — intervention group
Group type: COMPARATOR
Intervention: isotonic sodium chloride
Number of subjects: 39
Study 31811645 — intervention group
Group type: EXPERIMENTAL
Intervention: DPBM with adjunctive use of EMD (test group, n = 20)
Number of subjects: 42
Study 31811645 — intervention group
Group type: COMPARATOR
Intervention: DPBM without EMD (control group, n = 22)
Number of subjects: 42
Study 30551088 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifidus muscle pain
Number of subjects: 15
Study 30551088 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapezius muscle pain
Number of subjects: 15
Study 30551088 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapezius and multifidus muscle pain
Number of subjects: 15
Study 27307495 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 60
Study 27307495 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 60
Study 25400471 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate tablets (NaP, CLICOLONTM)
Number of subjects: 320
Study 25400471 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol solution (PEG)
Number of subjects: 320
Study 21981286 — intervention group
Group type: EXPERIMENTAL
Intervention: VIAject 7 (VJ7)
Number of subjects: 43
Study 21981286 — intervention group
Group type: COMPARATOR
Intervention: Insulin lispro (LIS)
Number of subjects: 43
Study 21981286 — intervention group
Group type: COMPARATOR
Intervention: VIAject 25 (VJ25)
Number of subjects: 43
Study 20445469 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain films
Number of subjects: 19
Study 20445469 — intervention group
Group type: COMPARATOR
Intervention: CT images
Number of subjects: 19
Study 20445469 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior ADI measurement
Number of subjects: 19
Study 20445469 — intervention group
Group type: EXPERIMENTAL
Intervention: Endplate method of angulation measurement
Number of subjects: 19
Study 20445469 — intervention group
Group type: EXPERIMENTAL
Intervention: Various measurements for odontoid fractures
Number of subjects: 19
Study 18646498 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam pre‐emptively administered
Number of subjects: 50
Study 18646498 — intervention group
Group type: COMPARATOR
Intervention: Control group (no meloxicam)
Number of subjects: 50
Study 16220356 — intervention group
Group type: EXPERIMENTAL
Intervention: Study intervention (not specified)
Number of subjects: 327
Study 16220356 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous quitting
Number of subjects: 327
Study 12370325 — intervention group
Group type: EXPERIMENTAL
Intervention: Photographs provided to participants (Intervention)
Number of subjects: 973
Study 12370325 — intervention group
Group type: COMPARATOR
Intervention: No photographs provided (Control)
Number of subjects: 973
Study 10197673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent antegrade warm blood cardioplegia with systemic normothermia (Group 2, n = 108)
Number of subjects: 200
Study 10197673 — intervention group
Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia with moderate systemic hypothermia (Group 1, n = 92)
Number of subjects: 200
Study 10197673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent antegrade warm blood cardioplegia (Group 2)
Number of subjects: 200
Study 10197673 — intervention group
Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia (Group 1)
Number of subjects: 200
Study 7767539 — intervention group
Group type: COMPARATOR
Intervention: Theophylline withdrawal
Number of subjects: 27
Study 7767539 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline treatment
Number of subjects: 27
Study 7767539 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline-naive patients
Number of subjects: 27
Study 7767539 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial biopsies
Number of subjects: 27
Study 1637611 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. tenoxicam 20 mg
Number of subjects: 20
Study 1637611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6610580 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenbufen (600 mg)
Number of subjects: 12
Study 6610580 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg)
Number of subjects: 12
Study 6610580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30076843 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 76
Study 30076843 — intervention group
Group type: COMPARATOR
Intervention: Argon plasma coagulation (APC)
Number of subjects: 76
Study 30266886 — intervention group
Group type: EXPERIMENTAL
Intervention: Venoplasty
Number of subjects: 104
Study 30266886 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 104
Study 27695824 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (200 mg continuous infusion for 5 days, followed by tapering until day 11)
Number of subjects: 380
Study 27695824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study 27695824 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 380
Study 23726851 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (1.5 mg a day)
Number of subjects: 535
Study 23726851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 535
Study 23726851 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pramipexole
Number of subjects: 535
Study 23726851 — intervention group
Group type: COMPARATOR
Intervention: Delayed pramipexole
Number of subjects: 535
Study 21849596 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg docosahexaenoic acid (DHA) + 150 mg eicosapentaenoic acid (fish oil)
Number of subjects: 0
Study 21849596 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg 5-methyltetrahydrofolate (5-MTHF)
Number of subjects: 0
Study 21849596 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DHA and 5-MTHF supplementation
Number of subjects: 0
Study 21849596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21849596 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher DHA in maternal erythrocytes at delivery
Number of subjects: 0
Study 19229530 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa/entacapone (LCE)
Number of subjects: 4
Study 19229530 — intervention group
Group type: COMPARATOR
Intervention: levodopa/carbidopa (LC)
Number of subjects: 4
Study 17926983 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5% desflurane in 50% N2O
Number of subjects: 72
Study 17926983 — intervention group
Group type: COMPARATOR
Intervention: 3% desflurane in 50% N2O
Number of subjects: 72
Study 15602380 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod
Number of subjects: 19
Study 15602380 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (Control)
Number of subjects: 19
Study 11512111 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg/night
Number of subjects: 10
Study 11512111 — intervention group
Group type: COMPARATOR
Intervention: Placebo 25 mg/night
Number of subjects: 10
Study 9762492 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect therapy
Number of subjects: 45
Study 9762492 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct with indirect therapy
Number of subjects: 45
Study 9762492 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 45
Study 7846776 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine balloon catheter
Number of subjects: 40
Study 7846776 — intervention group
Group type: COMPARATOR
Intervention: External cervical obturator
Number of subjects: 40
Study 2108889 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 or 7.5 mg leuprorelin acetate depot given subcutaneously once every 4 weeks
Number of subjects: 81
Study 7001332 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E therapy (25 mg daily by mouth for the first six weeks of life)
Number of subjects: 0
Study 7001332 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30715083 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compression
Number of subjects: 549
Study 30715083 — intervention group
Group type: COMPARATOR
Intervention: Standard compression
Number of subjects: 549
Study 28786042 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitting smoking or reducing average cigarette consumption to the mean level
Number of subjects: 0
Study 28786042 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported and clinically verified smoking measures
Number of subjects: 0
Study 28786042 — intervention group
Group type: EXPERIMENTAL
Intervention: Historic 5 years smoking behavior
Number of subjects: 0
Study 26059696 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy compliance reporting
Number of subjects: 115
Study 23934621 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1521498 20 mg
Number of subjects: 28
Study 23934621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 0.5 g/kg body weight
Number of subjects: 28
Study 23934621 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1521498 20 mg + Ethanol 0.5 g/kg body weight
Number of subjects: 28
Study 23934621 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 28
Study 21367761 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulphate (CS) 800 mg once daily for 6 months
Number of subjects: 69
Study 21367761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 18957312 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia group
Number of subjects: 30
Study 18957312 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 30
Study 17216272 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy followed by supervised exercise
Number of subjects: 90
Study 17216272 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercise alone
Number of subjects: 90
Study 15126148 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sildenafil (Viagra)
Number of subjects: 20
Study 15126148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11217092 — intervention group
Group type: EXPERIMENTAL
Intervention: Ninjin-to (6.0 g)
Number of subjects: 0
Study 11217092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9448590 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids and oral cyclophosphamide (CY; 2 mg/kg/day) for 1 yr (group A)
Number of subjects: 25
Study 9448590 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids and monthly i.v. CY pulses (0.6 g/m2) for 1 yr (group B)
Number of subjects: 25
Study 8092768 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF stimulation (without embryo transfer)
Number of subjects: 39
Study 8092768 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone support in unstimulated cycles
Number of subjects: 39
Study 8092768 — intervention group
Group type: COMPARATOR
Intervention: Control group (unstimulated cycles without progesterone)
Number of subjects: 39
Study 2179848 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy
Number of subjects: 1339
Study 384188 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy plus chemotherapy
Number of subjects: 58
Study 384188 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 58
Study 31335447 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed Intermittent Epidural Bolus (PIEB)
Number of subjects: 298
Study 31335447 — intervention group
Group type: COMPARATOR
Intervention: Patient-Controlled Epidural Analgesia (PCEA)
Number of subjects: 298
Study 26996268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 25758370 — intervention group
Group type: EXPERIMENTAL
Intervention: Zn + Se (ZS; 30 mg Zn as zinc‐gluconate and 200 μg Se as high‐selenium yeast)
Number of subjects: 68
Study 25758370 — intervention group
Group type: EXPERIMENTAL
Intervention: Zn + placebo (ZP)
Number of subjects: 68
Study 25758370 — intervention group
Group type: EXPERIMENTAL
Intervention: Se + placebo (SP)
Number of subjects: 68
Study 25758370 — intervention group
Group type: COMPARATOR
Intervention: placebo + placebo (PP)
Number of subjects: 68
Study 23628045 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined drug group treated with corticosteroid and anti-helicobacter pylori treatment
Number of subjects: 92
Study 23628045 — intervention group
Group type: COMPARATOR
Intervention: Single drug group treated only with corticosteroid
Number of subjects: 92
Study 21924013 — intervention group
Group type: EXPERIMENTAL
Intervention: SIPPV+VG
Number of subjects: 84
Study 21924013 — intervention group
Group type: EXPERIMENTAL
Intervention: HFOV
Number of subjects: 84
Study 21924013 — intervention group
Group type: COMPARATOR
Intervention: IMV
Number of subjects: 84
Study 18771564 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplement of 800 IU vitamin D from 27 weeks until delivery
Number of subjects: 180
Study 18771564 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 200,000 IU vitamin D
Number of subjects: 180
Study 18771564 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 180
Study 17098369 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Number of subjects: 59
Study 15054378 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (Ptx) 400 mg 3 times a day orally (total 1200 mg)
Number of subjects: 78
Study 15054378 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Ptx)
Number of subjects: 78
Study 15054378 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (Ptx)
Number of subjects: 78
Study 11432027 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional studies funded by GPEP
Number of subjects: 248
Study 11432027 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised trials funded by GPEP
Number of subjects: 248
Study 11432027 — intervention group
Group type: EXPERIMENTAL
Intervention: General practice research funding
Number of subjects: 248
Study 9597571 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose cyclophosphamide (2 g/m2), etoposide (600 mg/m2), and G-CSF 6 micrograms/kg/day (ID-Cy)
Number of subjects: 318
Study 9597571 — intervention group
Group type: COMPARATOR
Intervention: High-dose cyclophosphamide (4 g/m2), etoposide (600 mg/m2), and G-CSF 6 micrograms/kg/day (HD-Cy)
Number of subjects: 318
Study 9597571 — intervention group
Group type: COMPARATOR
Intervention: High-dose cyclophosphamide (HD-Cy)
Number of subjects: 318
Study 9597571 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose cyclophosphamide (ID-Cy)
Number of subjects: 318
Study 8062773 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma derived HB vaccine
Number of subjects: 174
Study 8062773 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant HB vaccine
Number of subjects: 174
Study 2890903 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 7-36 infusion
Number of subjects: 7
Study 2890903 — intervention group
Group type: COMPARATOR
Intervention: Control saline infusion
Number of subjects: 7
Study 2890903 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP infusion
Number of subjects: 7
Study 29742960 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg twice-daily
Number of subjects: 119
Study 29742960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 27737393 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation of bilateral femoral quadriceps muscles for 30 minutes during hemodialysis, three times per week, for two months
Number of subjects: 40
Study 27737393 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40